Literature DB >> 9060066

Probiotic treatment of small intestinal bacterial overgrowth by Lactobacillus fermentum KLD.

P O Stotzer1, L Blomberg, P L Conway, A Henriksson, H Abrahamsson.   

Abstract

The principle of using harmless bacteria for conquering pathogens has been used for many years. It has been used prophylactically against travellers' diarrhoea and for protection of recurrent pseudomembranous colitis. The aim of this study was to treat a chronic infectious condition, small intestinal bacterial overgrowth, by oral administration of a certain strain of Lactobacillus. 17 patients with long-standing bacterial overgrowth of the small intestine were included. The study was designed as a double-blind cross-over, where the patients were their own controls. The study was divided into 4 parts. (A) For the first 2 weeks placebo was given b.i.d. (B) For the next 4 weeks patients received either placebo or 10(10) Lactobacillus fermentum KLD b.i.d. (C) A wash-out period of 4 weeks followed. (D) Finally, for the second 4 week treatment period patients were crossed over to receive either lactobacilli or placebo. A hydrogen breath test with 50 g glucose was performed at the start and at the end of each period. Symptom scores were recorded on the last week of each period. The study was completed by 14 patients. Lactobacillus treatment showed no significant difference compared to placebo with respect to the results of the hydrogen breath test: 29 (3-95) vs 14 (3-129) ppm, (median and 10th and 90th percentiles), stool frequency: 14 (8-40) vs 12 (7-31) defecations/week. or symptom score: 12 (5-46) vs 17 (6-42) scores/week). High numbers of L. fermentum KLD in faecal samples were only seen in 2 patients. In conclusion, dosage with L. fermentum KLD in this study did not significantly alter the parameters investigated.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9060066     DOI: 10.3109/00365549609037970

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  10 in total

1.  Small Bowel Bacterial Overgrowth: Presentation, Diagnosis, and Treatment.

Authors:  Virmeet V. Singh; Phillip P. Toskes
Journal:  Curr Treat Options Gastroenterol       Date:  2004-02

Review 2.  Meta-analysis: antibiotic therapy for small intestinal bacterial overgrowth.

Authors:  S C Shah; L W Day; M Somsouk; J L Sewell
Journal:  Aliment Pharmacol Ther       Date:  2013-09-04       Impact factor: 8.171

3.  Aciduric Strains of Lactobacillus reuteri and Lactobacillus rhamnosus, Isolated from Human Feces, Have Strong Adhesion and Aggregation Properties.

Authors:  Kyle B Klopper; Shelly M Deane; Leon M T Dicks
Journal:  Probiotics Antimicrob Proteins       Date:  2018-03       Impact factor: 4.609

4.  The role of small intestinal bacterial overgrowth in cystic fibrosis: a randomized case-controlled clinical trial with rifaximin.

Authors:  Manuele Furnari; Alessandra De Alessandri; Federico Cresta; Maria Haupt; Marta Bassi; Angela Calvi; Riccardo Haupt; Giorgia Bodini; Iftikhar Ahmed; Francesca Bagnasco; Edoardo Giovanni Giannini; Rosaria Casciaro
Journal:  J Gastroenterol       Date:  2018-09-19       Impact factor: 7.527

Review 5.  Small Intestinal Bacterial Overgrowth in Patients With Cirrhosis.

Authors:  Gaurav Ghosh; Arun B Jesudian
Journal:  J Clin Exp Hepatol       Date:  2018-08-27

Review 6.  Small intestinal bacterial overgrowth syndrome.

Authors:  Jan Bures; Jiri Cyrany; Darina Kohoutova; Miroslav Förstl; Stanislav Rejchrt; Jaroslav Kvetina; Viktor Vorisek; Marcela Kopacova
Journal:  World J Gastroenterol       Date:  2010-06-28       Impact factor: 5.742

7.  Small intestinal bacterial overgrowth: a comprehensive review.

Authors:  Andrew C Dukowicz; Brian E Lacy; Gary M Levine
Journal:  Gastroenterol Hepatol (N Y)       Date:  2007-02

Review 8.  Small bowel bacterial overgrowth: presentation, diagnosis, and treatment.

Authors:  Virmeet V Singh; Phillip P Toskes
Journal:  Curr Gastroenterol Rep       Date:  2003-10

9.  The effects of the DDS-1 strain of lactobacillus on symptomatic relief for lactose intolerance - a randomized, double-blind, placebo-controlled, crossover clinical trial.

Authors:  Michael N Pakdaman; Jay K Udani; Jhanna Pamela Molina; Michael Shahani
Journal:  Nutr J       Date:  2016-05-20       Impact factor: 3.271

10.  Small Intestinal Bacterial Overgrowth: Clinical Features and Therapeutic Management.

Authors:  Satish S C Rao; Jigar Bhagatwala
Journal:  Clin Transl Gastroenterol       Date:  2019-10       Impact factor: 4.488

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.